← Oncology Approval Tracker

FDA DECISION ·

Zirabev + chemotherapy

bevacizumab-bvzr with indication-specific chemotherapy · Pfizer

FDA approvalNew or expanded indicationOvarian, fallopian tube and primary peritoneal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds use in stage III or IV epithelial ovarian, fallopian tube or primary peritoneal cancer after initial surgery with carboplatin and paclitaxel, then single-agent maintenance. Also adds specified chemotherapy combinations for platinum-sensitive recurrence and platinum-resistant recurrence after no more than two prior chemotherapy regimens.

LAMPGEN ANALYSIS

Why it matters

This extends the biosimilar label to several gynecologic cancer settings with different treatment backbones.

What research teams should watch

Verify surgical timing, platinum sensitivity, prior chemotherapy and the regimen listed for the applicable setting.

PRIMARY RECORDS

Sources